|
US20020055631A1
(en)
|
2000-09-20 |
2002-05-09 |
Augeri David J. |
N-acylsulfonamide apoptosis promoters
|
|
AR031130A1
(es)
|
2000-09-20 |
2003-09-10 |
Abbott Lab |
N-acilsulfonamidas promotoras de la apoptosis
|
|
WO2005049593A2
(en)
|
2003-11-13 |
2005-06-02 |
Abbott Laboratories |
N-acylsulfonamide apoptosis promoters
|
|
AU2005277223C1
(en)
|
2004-08-20 |
2009-05-21 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof
|
|
PL1888550T3
(pl)
|
2005-05-12 |
2014-12-31 |
Abbvie Bahamas Ltd |
Promotory apoptozy
|
|
MX2007014783A
(es)
|
2005-05-24 |
2008-02-19 |
Abbott Lab |
Activadores de apoptosis.
|
|
JP5277168B2
(ja)
|
2006-09-05 |
2013-08-28 |
アボット・ラボラトリーズ |
血小板過剰を治療するｂｃｌインヒビター
|
|
WO2009036051A1
(en)
|
2007-09-10 |
2009-03-19 |
Curis, Inc. |
Bcl-2 inhibitors containing a zinc binding moiety
|
|
US8501992B2
(en)
|
2008-06-09 |
2013-08-06 |
Bristol-Myers Squibb Company |
Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors
|
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
|
UA108193C2
(uk)
|
2008-12-04 |
2015-04-10 |
|
Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
|
|
US8563735B2
(en)
|
2008-12-05 |
2013-10-22 |
Abbvie Inc. |
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
|
DK2376480T3
(en)
|
2008-12-05 |
2016-09-12 |
Abbvie Inc |
Sulfonamide derivatives AS BCL-2-selective apoptosis inducing agents for the treatment of cancer and immune diseases
|
|
US8759520B2
(en)
|
2008-12-08 |
2014-06-24 |
Boehringer Ingelheim International Gmbh |
Compounds for treating cancer
|
|
CA2747835A1
(en)
|
2009-01-19 |
2010-07-22 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
WO2010083442A1
(en)
|
2009-01-19 |
2010-07-22 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
US8546399B2
(en)
|
2009-05-26 |
2013-10-01 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
WO2010138588A2
(en)
|
2009-05-26 |
2010-12-02 |
Abbott Laboratories |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
CA2772989A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
|
|
RU2015141713A
(ru)
|
2010-03-25 |
2018-12-28 |
Эббви Инк. |
Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний
|
|
TWI520960B
(zh)
|
2010-05-26 |
2016-02-11 |
艾伯維有限公司 |
用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
|
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
|
CA3152557A1
(en)
|
2010-10-29 |
2012-05-03 |
Abbvie Inc. |
Solid dispersions containing an apoptosis-inducing agent
|
|
IT1403156B1
(it)
|
2010-12-01 |
2013-10-04 |
Università Degli Studi Di Torino |
Inibitori di fosfatidilinositol 3-chinasi, relative composizioni ed usi.
|
|
EP2668180B1
(en)
|
2011-01-25 |
2018-08-01 |
The Regents of The University of Michigan |
Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
|
|
JP2014521595A
(ja)
|
2011-05-25 |
2014-08-28 |
ブリストル−マイヤーズ スクイブ カンパニー |
抗アポトーシスＢｃｌ阻害剤として有用な置換スルホンアミド
|
|
US8946445B2
(en)
|
2011-10-12 |
2015-02-03 |
Nanjing Allgen Pharma Co., Ltd. |
Heterocyclic molecules as apoptosis inducers
|
|
US9029820B2
(en)
|
2011-12-22 |
2015-05-12 |
Saint-Gobain Ceramics & Plastics, Inc. |
Image storage device including storage phosphor powder, method of forming image storage device, and computed radiography apparatus
|
|
BR112014015308A8
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos para inibição da interação de bcl2 com contrapartes de ligação
|
|
US9126980B2
(en)
|
2011-12-23 |
2015-09-08 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
EP2794592A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
WO2013096051A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
WO2013185202A1
(en)
|
2012-06-14 |
2013-12-19 |
Beta Pharma Canada Inc |
Apoptosis inducers
|
|
EP3689886A1
(en)
|
2013-01-16 |
2020-08-05 |
The Regents of The University of Michigan |
Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
|
|
US20140275082A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
CA2902686C
(en)
|
2013-04-25 |
2017-01-24 |
Beigene, Ltd. |
Fused heterocyclic compounds as protein kinase inhibitors
|
|
EA201690746A1
(ru)
|
2013-10-25 |
2016-12-30 |
Фармасайкликс Элэлси |
Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
|
|
PL3179991T3
(pl)
|
2014-08-11 |
2022-02-14 |
Acerta Pharma B.V. |
Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
|
|
WO2017132474A1
(en)
|
2016-01-30 |
2017-08-03 |
Newave Pharmaceutical Inc. |
Bcl-2 inhibitors
|
|
EP3481397A1
(en)
|
2016-07-06 |
2019-05-15 |
Concert Pharmaceuticals Inc. |
Deuterated venetoclax
|
|
US10829488B2
(en)
|
2016-08-05 |
2020-11-10 |
The Regents Of The University Of Michigan |
N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
|
|
WO2018041248A1
(zh)
|
2016-09-01 |
2018-03-08 |
北京赛林泰医药技术有限公司 |
Bcl-2选择性抑制剂及其制备和用途
|
|
CN106565706B
(zh)
|
2016-10-27 |
2018-05-01 |
广东东阳光药业有限公司 |
一种磺酰胺衍生物及其在药学中的应用
|
|
CN106749233B
(zh)
*
|
2016-11-24 |
2020-04-21 |
中山大学 |
一类磺酰胺衍生物及其应用
|
|
CN106809678B
(zh)
*
|
2017-01-03 |
2018-02-23 |
东莞理工学院 |
一种新旧smt接料带的粘接机
|
|
EP3565815B1
(en)
|
2017-01-07 |
2024-03-13 |
Fochon Pharmaceuticals, Ltd. |
Compounds as bcl-2-selective apoptosis-inducing agents
|
|
EP3612531B1
(en)
|
2017-04-18 |
2022-08-24 |
Shanghai Fochon Pharmaceutical Co., Ltd. |
Apoptosis-inducing agents
|
|
CN110759908B
(zh)
|
2017-06-26 |
2021-03-12 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用
|
|
CN111511748B
(zh)
|
2017-08-23 |
2023-05-02 |
广州麓鹏制药有限公司 |
Bcl-2抑制剂
|
|
FR3072679B1
(fr)
|
2017-10-25 |
2020-10-30 |
Servier Lab |
Nouveaux derives macrocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
CN110143974B
(zh)
|
2018-02-11 |
2021-07-13 |
中国科学院上海药物研究所 |
一类新型青蒿素衍生物、合成方法及其用途
|
|
SG11202009933WA
(en)
|
2018-04-29 |
2020-11-27 |
Beigene Ltd |
Bcl-2 INHIBITORS
|
|
CN114522167A
(zh)
|
2018-07-31 |
2022-05-24 |
苏州亚盛药业有限公司 |
Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
|
|
CA3095699A1
(en)
|
2018-07-31 |
2020-02-06 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
|
|
WO2020140005A2
(en)
*
|
2018-12-29 |
2020-07-02 |
Newave Pharmaceutical Inc. |
Bcl-2 inhibitors
|
|
WO2021083135A1
(en)
|
2019-10-28 |
2021-05-06 |
Beigene, Ltd. |
Bcl-2 INHIBITORS
|
|
WO2021110102A1
(en)
|
2019-12-02 |
2021-06-10 |
Beigene, Ltd. |
Methods of cancer treatment using bcl-2 inhibitor
|
|
IL296582A
(en)
*
|
2020-04-15 |
2022-11-01 |
Beigene Ltd |
bcl-2 inhibitor
|
|
CN116981668A
(zh)
*
|
2021-04-09 |
2023-10-31 |
百济神州(北京)生物科技有限公司 |
制备bcl-2抑制剂的中间体的方法
|
|
EP4351542A4
(en)
|
2021-06-02 |
2025-04-09 |
BeiGene Switzerland GmbH |
Method for treating B-cell malignancy with BCL-2 inhibitor
|
|
EP4396180A4
(en)
|
2021-08-31 |
2025-07-09 |
Beigene Ltd |
SOLID FORMS OF BCL-2 INHIBITORS, PROCESS FOR THEIR PREPARATION AND USE THEREOF
|
|
TW202400163A
(zh)
|
2022-05-12 |
2024-01-01 |
英屬開曼群島商百濟神州有限公司 |
使用ｂｃｌ－２抑制劑治療髓性惡性腫瘤之方法
|
|
JP2025525609A
(ja)
|
2022-07-21 |
2025-08-05 |
ベイジーン スイッツァランド ゲーエムベーハー |
Ｂｃｌ－２阻害剤を使用する多発性骨髄腫の治療方法
|